CASI Pharmaceuticals, Inc.
CASIF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962738
No open-market purchases or sales by CASI Pharmaceuticals, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $17 in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding CASI Pharmaceuticals, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 20 | 22 | +2 |
| Shares | 1.32M | 2.66M | +1.34M (+101.0%) |
| Value | $8.14M | $7.52M | −$615.8K (−7.6%) |
New holders (4)
Institutions that held CASI Pharmaceuticals, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Foresite Capital Management VI LLC | 1,329,383 | $3.76M | 1.68% |
| BNP Paribas Arbitrage, SA | 134 | $379 | 0.00% |
| MAI Capital Management | 5 | $15 | 0.00% |
| Wingate Wealth Advisors, Inc. | 2 | $6 | 0.00% |
Sold out (2)
Institutions that held CASI Pharmaceuticals, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Citadel Advisors LLC | 22,714 | $135.4K |
| Advisor Group Holdings, Inc. | 8 | $49 |